Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Psoriasis Drug Valuation By ICER May Undercut Routine Step Therapy

Executive Summary

Institute for Clinical and Economic Review issues final cost effectiveness report on psoriasis agents that improves the value rating earlier assigned to novel treatments based on a consideration of actual net prices.


Related Content

Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market
MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts – ICER Report
Is ICER Too NICE? A Comparison Of Drug Assessments Programs
Remicade Most Cost-Effective Biologic For Psoriasis In ICER Analysis
Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts